Hillman Capital Management Inc. Sells 3,618 Shares of Biogen Inc. $BIIB

Hillman Capital Management Inc. lessened its position in Biogen Inc. (NASDAQ:BIIB) by 8.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,354 shares of the biotechnology company’s stock after selling 3,618 shares during the quarter. Biogen accounts for 3.1% of Hillman Capital Management Inc.’s portfolio, making the stock its 14th largest position. Hillman Capital Management Inc.’s holdings in Biogen were worth $5,373,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Elevation Point Wealth Partners LLC bought a new position in shares of Biogen in the second quarter worth about $25,000. Rothschild Investment LLC lifted its holdings in Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 88 shares in the last quarter. Accredited Wealth Management LLC boosted its position in Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares during the period. WFA of San Diego LLC purchased a new stake in Biogen in the 2nd quarter valued at about $32,000. Finally, True Wealth Design LLC grew its stake in Biogen by 62.9% in the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BIIB shares. Wells Fargo & Company raised their target price on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. TD Cowen boosted their price target on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a report on Monday, February 9th. Truist Financial increased their price objective on Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a research note on Monday, February 9th. Barclays initiated coverage on Biogen in a research report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 target price for the company. Finally, HC Wainwright increased their price target on Biogen from $194.00 to $228.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Twelve analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $205.04.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.18% of the company’s stock.

Biogen Stock Performance

Shares of Biogen stock opened at $181.55 on Monday. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $202.41. The company has a 50 day moving average price of $184.10 and a 200 day moving average price of $167.19. The firm has a market capitalization of $26.64 billion, a P/E ratio of 20.61, a PEG ratio of 1.44 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the prior year, the firm posted $3.44 EPS. The business’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Sell-side analysts expect that Biogen Inc. will post 15.83 EPS for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.